Method and apparatus for emission guided radiation therapy

Abstract
An apparatus comprising a radiation source, coincident positron emission detectors configured to detect coincident positron annihilation emissions originating within a coordinate system, and a controller coupled to the radiation source and the coincident position emission detectors, the controller configured to identify coincident positron annihilation emission paths intersecting one or more volumes in the coordinate system and align the radiation source along an identified coincident positron annihilation emission path.
Description
FIELD OF TECHNOLOGY

This disclosure relates to apparatus and method for radiation therapy and more particularly to apparatus and method for treating cancer tissue in the body using high energy radiation.


BACKGROUND

Radiation therapy (RT) is a method for treating cancerous tissue in the body using high energy radiation (e.g. x-rays) to kill tumor cells. There are two main types of RT: internal beam and external beam. Internal beam RT is achieved by implanting radioactive material within the patient inside or near the cancerous site to be treated. External beam RT is achieved by aiming a high energy beam of radiation through the patient so that it passes through the region to be treated. External RT has evolved significantly over the past few decades. In an effort to apply a lethal radiation dose to a tumor while sparing healthy tissue, techniques such as three-dimensional conformal beam RT are used to shape the beam to match the two-dimensional projection of the tumor onto the patient surface. Furthermore, the beam is applied at various angles around the patient and with varying intensities so as to maximize dose to the tumor while minimizing dose to the surrounding healthy tissue. This is known as intensity-modulated RT (IMRT).


However, uncertainty associated with tumor location and motion can limit effectiveness of external beam RT. Static errors arise from patient setup variability as well as natural changes in the tumor location due to shifting of the internal organs. These can change between treatments. Dynamic errors arise from tumor motion during treatment (e.g. due to patient breathing). Lung tumors, for example, are known to move on the order of 1-2 cm during normal patient respiration. This continuing problem has resulted in a new class of RT systems: image-guided RT (IGRT). These techniques involve imaging the tumor region using a conventional medical imaging modality (x-ray, CT, MRI, PET, etc.) both before and sometimes simultaneously during treatment so that the tumor location can be known at the time of treatment.


IGRT techniques, however, suffer either from a lack of specificity of the tumor imaging (e.g. in many cases it is nearly impossible to visualize the tumor boundaries from x-ray CT), or from poor temporal resolution (PET is the most sensitive modality to imaging cancer however it take minutes to form a good quality PET image). In either case, it is still very difficult to dynamically track a tumor during RT.


Positron emission tomography (PET) is a medical imaging modality that is frequently used to detect cancerous tissue in the body. A molecule labeled with a radioactive atom, known as a PET radiotracer, is first injected into the patient. The radioactive atoms inside the patient undergo radioactive decay and emit positrons. Once emitted from an atom, a positron will quickly collide with a nearby electron after which both will be annihilated. Two high energy photons (511 keV) are emitted from the point of annihilation and travel in opposite directions. When the two photons are simultaneously detected by two PET cameras, it is known that the annihilation occurred somewhere along the line joining the two PET cameras. This line is called a positron annihilation emission path. The information collected from thousands of these emission paths is used to gradually assemble an image of the PET radiotracer distribution in the body. The most commonly used PET radiotracer is fluorine-18 fluorodeoxyglucose (FDG). This is a glucose substitute and therefore is used to image the rate of metabolic activity in the body. Because cancerous tissue tends to be more metabolically active then healthy tissue, there is an increase in FDG uptake in a tumor relative to normal tissue and therefore an increase in the PET signal. FDG-PET is one of the most sensitive imaging modalities that can be used to detect the presence of cancer. It is used extensively for both diagnosis of cancer and monitoring of therapy. However, it is impractical to use PET simultaneously with external beam RT. PET imaging takes on the order of 10 minutes to acquire an image of reasonable quality which severely limits the use of PET as an agent for dynamic tracking of tumor position.


SUMMARY

The present subject matter relates to apparatus and method for scanning and aligning radiation along coincident positron annihilation emission paths. A method includes detecting a coincident positron annihilation emission path from a radioactive event intersecting a predetermined volume during a session, and aligning a radiation source along the emission path during the session. Various examples include repeated, timely alignment of radiation in response to individual detected emission events. Various examples include receiving location data to identify predetermined volumes and avoid directing radiation to radiation sensitive areas.


An apparatus is provided for aligning radiation during a radiation session. The apparatus comprising a radiation source, coincident positron emission detectors configured to detect coincident positron annihilation emissions originating within a coordinate system, and a controller in communication with the radiation source and the coincident positron emission detectors, the controller configured to identify coincident positron annihilation emission paths intersecting one or more volumes within the coordinate system and to align the radiation source along an identified coincident positron annihilation emission path.


This Summary is an overview of some of the teachings of the present application and is not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and the appended claims. The scope of the present invention is defined by the appended claims and their legal equivalents.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows an apparatus for aligning radiation along positron annihilation emission paths according to one embodiment of the present subject matter.



FIG. 2 is a flowchart for a method of aligning radiation along coincident positron annihilation emission paths according to one embodiment of the present subject matter.



FIG. 3 is a flowchart for a method of aligning and directing a prescribed dose of radiation according to one embodiment of the present subject matter.



FIG. 4A-4D illustrates an apparatus for aligning radiation along positron annihilation emission paths according to one embodiment of the present subject matter.



FIG. 5 shows a collimator assembly according to one embodiment of the present subject matter.



FIGS. 6A-6C shows a C-arm gantry for aligning radiation along positron annihilation emission paths according to one embodiment of the present subject matter.





DETAILED DESCRIPTION

The following detailed description of the present invention refers to subject matter in the accompanying drawings which show, by way of illustration, specific aspects and embodiments in which the present subject matter may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the present subject matter. References to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope is defined only by the appended claims, along with the full scope of legal equivalents to which such claims are entitled.


The present subject matter relates to a new class of techniques termed emission guided radiation therapy (“EQRT”). One EGRT method includes using an emission modality that is highly sensitive to cancer directly during the treatment stage by responding to individual emission events using a beam of radiation along the detected path of emission. If the radiation response occurs within a sufficiently short time period after the emission detection, the tumor site will not have moved substantially and will be irradiated. Thus, tumor tracking is inherently achieved in emission guided radiation therapy and complete knowledge of the actual tumor location or motion is not required. By responding to a series of emission events from the tumor site with a series of respective radiation beams, treatment can be achieved effectively irrespective of tumor location uncertainty. It is also possible to treat more than one tumor simultaneously in this fashion. In addition, the same pre-planning procedure as is employed for current RT protocols may be earned out to identify a volume within which the tumor will always be present (including its motion) so that no radiation, or minimal radiation, is applied to regions where the tumor is not present, and/or so that treatment avoids radiation sensitive organs in the body.



FIG. 1 shows an apparatus for sensing and aligning radiation along detected positron annihilation emission paths according to one embodiment of the present subject matter. In various embodiments, the apparatus 130 includes a circular moveable gantry supported by a frame (not shown), a radiation source 131, position annihilation emission sensors 133, a motion system 134 and a controller 135. In various embodiments, the apparatus includes x-ray detectors 132 positioned opposite the radiation source to measure radiation applied to a volume of interest 138. The radiation source 131, x-ray detectors 132 and positron emission sensors 133 are mounted to the moveable gantry. The positron emission sensors 133 are mounted on the gantry between the radiation source 131 and the x-ray detectors 132. In various embodiments, the apparatus includes x-ray and positron emission sensors combined so that the positron emission detectors provide sensing capability around substantially the entire gantry circle from one side of the radiation source to the other. In one embodiment, the x-ray detectors include, but are not limited to high energy, mega-electron Volt (MeV) detectors. The positron emission sensors 133 are adapted to detect positron annihilation events by sensing coincident photon paths 136 emitted during the events. In various embodiments, the motion system moves the gantry and attached equipment about the volume 138 to align the radiation source with the path of the detected emission. The controller 135 is connected to the radiation source 131, positron emission sensors 133, x-ray detectors 132 and the motion system 134. The controller 135 identifies coincident photon emission paths 136 intersecting an identified volume 138 and coordinates the alignment, configuration and triggering of the radiation source 131 to direct radiation to the volume 138 along the identified emission paths. In various embodiments, the controller receives location information for one or more volumes of interest 138 to limit any applied therapy to a region of interest. In various embodiments, the controller is programmed with one or more volumes that the system will not irradiate. Some examples of these volumes include radiation sensitive areas to protect from radiation, or perhaps an area which was treated previously and which needs to be untreated in any particular session. In some embodiments, volumes of interest 138 are identified in a first phase of a radiation session by detecting several positron annihilation emissions and mapping the activity. In various embodiments, the radiation source includes a collimation assembly 139 for shaping and precisely directing the radiation from the radiation source.


In various embodiments, the controller moves the radiation source, the positron emission detectors, or both the radiation source and the positron emission detectors using a common coordinate system. In one embodiment, the positron emission detectors are stationary and the radiation source is moveable using a robotic motion system referenced to a common coordinate system. In some embodiments, the radiation source and the positron emission detectors are both moveable and use separate motion systems referenced to a common coordinate system. It is understood that various motion systems are possible for moving the radiation source, the positron emission detectors or both the radiation source and the positron emission detectors without departing from the scope of the present subject mutter including, circular gantries, rectilinear gantries, articulated arm robots, custom robotics or combinations thereof.



FIG. 2 is a flowchart of a method 250 for scanning a volume during a radiation session according to one embodiment of the present subject matter. Often, a tumor is imaged a substantial period of time before undergoing radiation therapy. During therapy, radiation is directed to the location the tumor was at when last imaged. Tumors can migrate substantial distances in relatively short intervals of time. Such migrations can result from such innocuous events as a patient changing posture, coughing or even breathing. A typical goal of radiation therapy is to apply enough radiation to the tumor so as to kill the tumor tissue while also minimizing radiation applied to non-tumor tissue. If the tumor moves after it has been imaged, some radiation may miss the tumor during radiation, thus, some portions of the tumor may survive treatment and some healthy tissue may receive lethal amounts of radiation. Additionally, if during treatment, radiation is applied to portions of the tumor that are dead, the patient will be enduring more radiation than is necessary. In medical applications, the present method provides real-time tracking of live tumor tissue and direction of radiation to the tumor tissue. The method 250 includes detecting coincident positron annihilation emission paths from a radioactive event intersecting a volume 251 and aligning a radiation source along the emission path 252. In various embodiments, the method includes directing radiation along the detected emission path to the volume before the content of the volume moves substantially. In medical applications, applying radiation along the detected positron annihilation emission path in a timely manner provides certainty that the radiation therapy is applied to living tumor tissue; even if the tumor has migrated since last imaged.



FIG. 3 is a flow chart of a method 360 for directing a predetermined dose of external radiation to a volume of interest during a radiation session according to one embodiment of the present subject matter. The method includes receiving location data describing one or more volumes of interest 361. In various situations, the data is generated during a pre-treatment planning stage. In some situations, substantial imaging has been done to diagnose and track a volume of interest such as an area of diseased tissue. This imaging can be used to establish probable volumes within which tumors of interest exist and move. The data may be generated from imaging completed during diagnosis. In some embodiments, location data of more than one volume is received such that radiation may be directed to several volumes during a session. Identifying volumes of interest, such as cancerous tumor tissue, for example, may include a number of modalities including, but not limited to, X-Ray imaging, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) or combinations thereof. Other modalities are possible without departing from the scope of the present subject matter.


In various embodiments, prior to a radiation session, a volume of interest is provided with a radiotracer. The radiotracer provides a source of positrons for real-time tracking of the volume. The method then commences with receiving location data of the volumes 361, if not already received. In various embodiments, receiving the location data of the volume includes registering the volume with a reference point of the machine, such as the radiation source, for example. In various embodiments, registering the volume with the machine includes performing a low dose CT scan using the machines radiation source. In some embodiments, receiving location data of one or more volumes and registering each volume with the machine includes detecting a number of emission events and mapping the events to identify the volumes. It is understood that other methods of registering a volume with the external radiation machine are possible without departing from the scope of the present subject matter. In some embodiments, receiving location data of the volumes includes receiving location data of areas not to irradiate.


The method further includes detecting coincident emission paths from a positron annihilation event intersecting a volume of interest 362, aligning the radiation source along the detected emission path 363 and then directing radiation along the detected emission path to the volume 364. In various embodiments, upon detection of an emission event, the downloaded location data are used to determine whether the event intersected a volume of interest.


In various embodiments, the radiation source and emission detectors move about the one or more volumes to allow tor detection of emission events and direction of radiation from multiple angles. Directing radiation to a volume from multiple angles minimizes exposure of intervening material, such as healthy tissue, to radiation. In various embodiments, prior imaging is used to regulate intensity of the radiation source to account for the depth of the volume within other material. In various embodiments, as the session progresses, the controller analyzes and constructs a map of one or more volumes of interest from the emission events detected during the session. In various embodiments, as the map becomes more detailed, the controller selectively aligns and directs radiation along detected emission paths based on the map.


Upon directing radiation toward a volume, a controller records the amount or dose of radiation directed to the patient 365. In various embodiments, x-ray detectors located opposite the radiation source record the radiation directed toward and passing through the volume. The controller monitors the accumulated radiation and continues to detect emission events and direct radiation along detected emission paths until a prescribed dosage of radiation has been directed to each volume of interest 366. In various embodiments, accumulation of the detected position emission events can be used to image the volume of interest and surrounding material. In medical applications, accumulation of the detected positron emission events can be used to construct an image of metabolic activity of the volume. In some embodiments, the image data may be used to modify subsequent treatment.


In various embodiments, such as those used in medical applications, volumes of interest, such as cancerous tumor tissue, are provided with a radiotracer as a source of positrons for real time tracking of the volume. A typical radiotracer includes unstable nuclides which emit positrons. The positron has the same mass as an orbital electron but is positively charged. A unique characteristic of the positron is that it can not exist at rest in nature. Once it loses its kinetic energy, the positron immediately combines with a negatively charged electron and undergoes an annihilation reaction in which the masses of the two particles are completely converted into energy in the form of two 0.511-MeV annihilation photons, which leave their production site at approximately 180 degrees from each other. The detection of the two 511-keV gamma rays forms the basis for targeting living tumor tissue with radiotracers.


A commonly used radiotracer in clinical practice and the study of cancers is fluorine-18 fluorodeoxyglucose (FDG), a metabolic PET radiotracer. FDG, a glucose analog, is taken up by high-glucose-using cells such as brain, kidney, and cancer cells, where phosphorylation prevents the glucose from being released intact. Thus, living diseased tissue will take up, and concentrate metabolic PET radiotracers more intensely than healthy tissue. Because dead tissue does not take up the radiotracer, an added benefit of a metabolic radiotracer is that it provides real-time tracking of the living tissue of the tumor. As a result, in applying the radiation therapy along detected emission paths, the method provides a high degree of certainty that the radiation is applied precisely to not only the tumor, but to the living tissue of the tumor. It is understood that the use of other radiotracers with positron-emitting radionuclide are possible without departing from the scope of the present subject matter including, but not limited to, Fluorine-18, Carbon-11, Oxygen-15, and Nitrogen-13.



FIGS. 4A-4D show a cross section of an apparatus 401 for detecting coincident positron annihilation emissions paths and aligning radiation to the emission paths according to one embodiment of the present subject matter. FIGS. 4A-4D includes a patient 420 positioned within the apparatus 401. The patient has living tumor tissue within a volume 422 to be irradiated. The apparatus includes a controller 407, a radiation source 402 to produce high energy radiation, a collimation assembly 410 to assist shaping and precisely directing the high energy-radiation, an array of x-ray detectors 408, and an array of positron emission tomography (PET) sensors 404. The radiation source 402, collimation assembly 410, x-ray detectors 408 and PET sensors 404 are situated on a rotating gantry 406. The gantry 406 is mounted to a stationary frame (not shown). In various embodiments, a motion control system 409 connected to the controller 407 moves the gantry 406 and mounted equipment about the patient 420.



FIG. 4B shows the apparatus 401 performing a low dose, MeV CT scan to register the patient's position relative to the apparatus 401. Anatomic landmarks or other marking schemes may be used to register the patient's body position with the apparatus. Registration allows the controller to relate the geometric coordinates of the volume(s) of interest, including those volumes not to be irradiated, with the geometric coordinates of the apparatus 401. After registration, the controller 407 controls the apparatus 401 in monitoring positron annihilation emission paths intersecting the volume 422, aligning the radiation source to the emission paths and directing radiation along detected emission paths. While monitoring for positron annihilation events, the radiation source 402, collimation assembly 410, PET sensors 404 and high energy radiation detectors 408 rotate around the patient using the motion system 409 connected to the controller 407.



FIG. 4C shows detection of a coincident positron emission path 412 intersecting the volume 422. Upon detection of a coincident emission event and path 412, the controller 407, records the geometric coordinates of the coincident emission path. If the detected path 412 intersects a volume of interest 422, the controller 407 initiates alignment of the radiation source and triggers radiation along the path of the emission after the motion system has moved the radiation source 402 into alignment with the emission path 412. Applying the radiation along the same path as the emission provides a high degree of certainty that the radiation is applied precisely to living tissue of the tumor. In addition to moving the radiation source to the angle of a detected emission, alignment includes configuring the collimation assembly 410 to precisely direct the radiation along the positron emission path. In various embodiments, precise and timely alignment of the radiation includes reconfiguring the collimation assembly while the gantry 406 is rotating about the patient.



FIG. 4D shows the apparatus directing radiation along a detected emission path according to one embodiment of the present subject matter. The controller coordinates the motion of the gantry, configuration of the collimation assembly and triggering of the radiation source to provide radiation 414 from the radiation source 402 along the same path as detected positron emission paths. The collimation assembly 410 allows the radiation beam to be fragmented so that desired rays in the fan-beam may pass through while others are completely occluded. Reconfiguration of the collimation assembly occurs quickly so that a new configuration is possible for each angular position of the radiation source 402 around the gantry 406.


As the gantry 406 rotates, detection, alignment and triggering of radiation is repeated for multiple positron emission events until a desired radiation dose is achieved in each volume of interest. In various embodiments, the controller records readings received from the x-ray detectors 408 to verify the total radiation dosage. It is understood that x-ray detectors may be formed of one or more high energy detectors including, but not limited to, MeV detectors, high energy kilo-electron volt (keV) detectors or combinations thereof.


In various embodiments, the controller 407 includes data about the location of one or more tumors. In such embodiments, the controller coordinates detection of emission events and triggering and directing of radiation to the multiple volumes. In various embodiments, volume location data is downloaded into the controller from previous imaging. The data allows the controller to determine with a high degree of certainty whether a detected emission event path intersects with a volume of interest.


As discussed above, when position emission events intersecting a volume of interest are detected, the controller 407 reconfigures the collimation assembly 410 to allow radiation from the radiation source 402 to follow the same path as the detected emission path within a specified time. In various embodiments, reconfiguration of the collimation assembly is accomplished on-the-fly as the gantry 406 rotates the radiation source 402 and sensors 404, 408 about the patient 420. Speed of the gantry rotation, processing delay of the controller, and location of the radiation source upon detection of an emission event are some factors that determine the delay between the emission event and directing and triggering radiation along the emission path. In medical applications, alignment of the radiation source to emission paths increases tracking accuracy of tumors even for motion of the tumors resulting from normal body functions such as breathing. In some embodiments, the gantry includes multiple radiation sources. Multiple radiation sources allow treatment to be completed more quickly, allow delay reduction between detection of an emission event and alignment of a radiation source or both quicker treatment and reduced delay.


In various embodiments, the apparatus aligns and directs radiation in response to individual positron annihilation events. In various embodiments, the controller queues detected positron annihilation emissions as the gantry rotates, aligns and directs radiation to previously detected emission paths. In some embodiments, the radiation source is aligned and directed sequentially along selected queued paths. In some embodiments, the radiation source is aligned and directed along selected queued paths depending on the present position of the radiation source about the volume, such that a more recently detected path may be selected because the radiation source will approach that path before an earlier detected path. In some embodiments, the controller queues selected emission paths for an interval of time and then aligns and directs radiation along selected paths of the queue before repeating the process by queuing additional emission paths. By adjusting the desired time interval between sensing an event and delivering radiation along the detected emission path, the apparatus can establish a queue of different numbers of radiation delivery paths. It can also use algorithms to provide the radiation with the least amount of movement of the apparatus. Other algorithms and procedures are possible without departing from the scope of the present subject matter.


In some embodiments, the controller paces alignment and triggering of the radiation source to cyclical functions of the patient such as breathing. For example, assume the breathing cycle of a patient has been sensed to repeat every few seconds. As the controller senses emission events intersecting a volume of interest, the controller records the phases of the breathing cycle in which these events occurred and controls a coordinated delay in moving, aligning and triggering the radiation source to coincide with the same phases of the breathing cycle.


Various embodiments of the present subject mailer align and direct radiation in a 2-D or a 3-D mode. In a 2-D mode, a multi-leaf radiation collimator is reconfigured for each specified angular position of the radiation source so that radiation paths lie within a fan whose vertex is at the source of radiation. FIG. 5 shows a collimator assembly 550 according to one embodiment of the present subject matter. A pair of collimator jaws 551 immediately preceding the multi-leaf collimator 553 restricts the conical divergence 554 of the radiation source 555 to a particular plane 552. Operation of the lower jaws 553 allows alignment of the radiation to multiple volumes within the plane of the radiation path. In various embodiments, a table may be translated in a continuous fashion or in a step-and-shoot fashion to treat multiple slices of a volume. If the table is translated continuously, the table speed should allow for a prescribed dose to each volume.


In the case of an apparatus employing a 3-D mode of treatment, the collimator jaws 551 restricting the conical radiation beam divergence 554 may be moved in coordination with the collimation assembly leaves 553. Although radiation is restricted to a particular plane, coordinated motion of the collimation assembly jaws allow various planes of treatment for a given position of the radiation source. For circular gantries and C-Arm apparatus, 3-D mode allows the collimation assembly to provide radiation at angles oblique to the central axis of the apparatus. Additionally, for a given position of the apparatus, the 3-D mode allows the controller to respond to multiple coincident emission paths within a larger portion of the field of view of a PET sensor array compared to 2-D mode.



FIGS. 6A-6C shows a C-arm gantry apparatus 660 according to one embodiment of the present subject matter. The apparatus 660 includes a radiation source 661, collimation assembly 662 and PET cameras 663 mounted to a rotary section 664 of the apparatus. A fixed section 665 of the apparatus provides support for the rotary section 664. FIG. 6A shows a front view of the apparatus with the radiation source located above a table 666 and the PET cameras 663 positioned at either side of the table 666. A controller (not shown) provides control and coordination of the radiation source 661, collimation assembly 662, PET cameras 663, and motion as the rotating section 664 moves the devices about the table 666. FIG. 6B shows a front view of the apparatus with the radiation source 661, collimation assembly 662 and PET cameras 663 rotated 90 degrees about the table 666. For 3-D mode treatment, a multi-leaf x-ray collimator is reconfigured for each specified angular position of the radiation source so that the radiation paths lie within a cone whose vertex is at the source of radiation.


In various embodiments, in order to treat multiple slices of a volume, the table 666 may by translated in a continuous fashion or in a step and shoot mode. FIG. 6C shows a side view of the C-arm gantry apparatus 660 with the table 666 translated toward the apparatus. In various embodiments, where the table is translated continuously, table speed is controlled to allow for a prescribed dose of radiation to be directed to each volume.


In various embodiments, the apparatus 660 includes high energy (MeV) detectors located opposite the radiation source to record and verify the amount, or dose, of radiation directed to each volume. In some embodiments, instead of MeV detectors, combined MeV/PET detectors are used. Combined MeV/PET detectors allow detection of both 511 keV PET emissions as well as high energy radiation. Such an arrangement increases the coverage of the PET detectors and allows for a faster radiation session. It is understood that other combinations of PET and high energy x-ray detectors are possible without departing from the scope of the present subject matter including but not limited to keV/PET detectors.


In various embodiments, the radiation includes x-rays produced by a linear accelerator (linac). Other radiation types and radiation sources are possible for providing radiation without departing from the scope of the present subject matter. Such radiation and radiation sources include, but are not limited to, high energy photons, radiation or particles produced by a radioactive isotope (e.g. iridium or cobalt60), high energy electrons, a proton beam, a neutron beam and a heavy ion beam.


In one embodiment, the apparatus is implemented using a single photon emission computed tomography (SPECT) setup with pinhole cameras and/or collimated SPECT sensors in place of the PET sensors to detect the direction of emitted photons from a radioactive event.


In one embodiment, the radiation source does not rotate. Radiation sources (e.g. lead encased cobalt60) are placed all around the gantry, alternating with the PET detectors. In this case, radiation from a particular radiation source would follow the emission path detected by an adjacent PET sensor pair.


In one embodiment, two or more radiation sources are affixed to the rotating gantry. The controller aligns each of the radiation sources to respond to distinct emission paths. Multiple radiation sources permit a smaller time window between detecting an emission path and directing radiation along that path, than if only a single radiation source is used.


In various embodiment, the apparatus provides other modes of radiation therapy for stand alone operation, or for simultaneous operation with emission guided radiation therapy. Other modes of radiation therapy include, but are not limited to, radiation treatment based on prior imaging of the treatment volumes, three-dimensional conformal beam RT, intensity-modulated RT or combinations thereof.


This application is intended to cover adaptations and variations of the present subject matter. It is to be understood that the above description is intended to be illustrative, and not restrictive. The scope of the present subject matter should be determined with reference to the appended claims, along with the full scope of legal equivalents to which the claims are entitled.

Claims
  • 1. A method for delivering radiation, the method comprising: receiving location data of a volume of interest located on a table, wherein the volume of interest comprises tumor tissue;detecting a plurality of positron annihilation emission paths using a plurality of positron emission detectors on a gantry that is rotatable about the table;identifying positron annihilation emission paths from the plurality of detected positron annihilation emission paths that intersect with the volume of interest; anddelivering radiation to the tumor tissue by translating the table in steps, and at each table step, directing radiation using a therapeutic radiation source to a portion of the tumor tissue based on the identified positron annihilation emission paths.
  • 2. The method of claim 1, wherein the portion of tumor tissue comprises a slice of tumor tissue that is located within a treatment beam plane of the therapeutic radiation source.
  • 3. The method of claim 1, wherein delivering radiation to the tumor tissue comprises directing radiation in response to multiple positron annihilation emission paths that intersect the volume of interest.
  • 4. The method of claim 3, wherein directing radiation comprises emitting a series of radiation beams to the volume of interest with partial knowledge of actual tumor tissue location or motion.
  • 5. The method of claim 3, further comprising generating a map of photon emission activity.
  • 6. The method of claim 5, wherein receiving location data of the volume of interest comprises identifying the volume of interest by detecting a plurality of positron annihilation emission paths and generating a map of photon emission activity.
  • 7. The method of claim 1, wherein the location data of the volume of interest is determined during treatment planning.
  • 8. The method of claim 1, wherein identifying positron annihilation emission paths comprises comparing each detected emission path with the location data of the volume of interest.
  • 9. The method of claim 1, wherein detecting the plurality of positron annihilation emission paths comprises rotating the plurality of positron emission detectors about the volume of interest while detecting the plurality of positron annihilation emission paths.
  • 10. The method of claim 1, wherein directing radiation to the portion of the tumor tissue based on the identified positron annihilation emission paths comprises directing radiation along one or more of the identified positron annihilation emission paths.
  • 11. The method of claim 1, further comprising receiving second location data of a second volume of interest, wherein the second volume of interest comprises a second tumor tissue;detecting a second plurality of positron annihilation emission paths using the plurality of positron emission detectors;identifying a second set of positron annihilation emission paths from the second plurality of detected positron annihilation emission paths that intersect with the second volume of interest; anddelivering radiation to the second tumor tissue by translating the table in steps, and at each table step, directing radiation to a portion of the second tumor tissue based on the second set of identified positron annihilation emission paths.
  • 12. The method of claim 11, wherein the therapeutic radiation source is mounted on the rotatable gantry, and wherein delivering radiation to the first tumor tissue and the second tumor tissue comprise directing radiation from the therapeutic radiation source from multiple gantry positions.
  • 13. The method of claim 1, wherein the tumor tissue comprises living tumor tissue.
  • 14. The method of claim 1, wherein the tumor tissue comprises lung tumor tissue.
  • 15. The method of claim 1, wherein the volume of interest comprises kidney tissue.
  • 16. The method of claim 1, wherein the volume of interest comprises brain tissue.
  • 17. The method of claim 1, further comprising providing a positron-emitting radionuclide to the tumor tissue.
  • 18. The method of claim 17, wherein the positron-emitting radionuclide is selected from the group consisting of fluorine-18, carbon-11, oxygen-15, and nitrogen-13.
  • 19. A radiotherapy system comprising: a gantry;a movable table, wherein the gantry is rotatable about the table;a plurality of positron emission detectors mounted on the gantry and configured to detect a plurality of positron annihilation emission paths;a therapeutic radiation source mounted on the gantry; anda controller in communication with the gantry, the movable table, the positron emission detectors, and the therapeutic radiation source, wherein the controller is configured to receive location data of a volume of interest that is located on the table, wherein the volume of interest comprises tumor tissue,identify positron annihilation emission paths from the plurality of detected positron annihilation emission paths that intersect with the volume of interest, andtranslate the table in steps while delivering radiation to multiple portions of the tumor tissue based on the identified positron annihilation emission paths.
  • 20. The system of claim 19, wherein the portion of tumor tissue comprises a slice of tumor tissue that is located within a treatment beam plane of the therapeutic radiation source.
  • 21. The system of claim 19, wherein delivering radiation comprises directing radiation in response to multiple positron annihilation emission paths that intersect the volume of interest.
  • 22. The system of claim 21, wherein directing radiation comprises emitting a series of radiation beams to the volume of interest with partial knowledge of actual tumor tissue location or motion.
  • 23. The system of claim 19, wherein delivering radiation comprises directing radiation along one or more of the identified positron annihilation emission paths.
  • 24. The system of claim 19, wherein the location data of the volume of interest is determined during treatment planning.
  • 25. The system of claim 19, wherein identifying positron annihilation emission paths comprises comparing each detected emission path with the location data of the volume of interest.
  • 26. The system of claim 19, wherein the positron emission detectors are configured to detect the plurality of positron annihilation emission paths while being rotated about the volume of interest.
  • 27. The system of claim 19, wherein the controller is configured to direct the therapeutic radiation source to deliver radiation while rotating the gantry and detecting positron annihilation emission paths.
  • 28. The system of claim 27, wherein the plurality of positron annihilation emission detectors is configured to detect positron annihilation emission paths from multiple tumor regions, and wherein the controller is configured to direct the therapeutic radiation source to delivery radiation to the multiple tumor regions from multiple gantry positions.
  • 29. The system of claim 19, further comprising a collimation assembly mounted on the gantry and disposed in a radiation path of the therapeutic radiation source, wherein the configuration of the collimation assembly is adjustable while the gantry is rotating.
  • 30. The system of claim 29, wherein the controller is in communication with the collimation assembly and the collimation assembly comprises a multi-leaf collimator and collimator jaws.
  • 31. The system of claim 30, wherein the multi-leaf collimator is reconfigurable for each gantry position.
  • 32. The system of claim 31, wherein the controller is further configured to move the collimator jaws in coordination with the multi-leaf collimator.
  • 33. The system of claim 19, further comprising a plurality of therapeutic radiation sources mounted on the gantry.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/807,383, filed Nov. 8, 2017, now U.S. Pat. No. 10,327,716, which is a continuation of U.S. patent application Ser. No. 14/951,194, filed Nov. 24, 2015, now U.S. Pat. No. 9,820,700, which is a continuation of U.S. patent application Ser. No. 14/278,973, filed May 15, 2014, now U.S. Pat. No. 9,205,281, which is a continuation of U.S. patent application Ser. No. 13/895,255, filed May 15, 2013, now U.S. Pat. No. 8,748,825, which is a continuation of U.S. patent application Ser. No. 13/209,275, filed Aug. 12, 2011, now U.S. Pat. No. 8,461,538, which is a continuation of U.S. patent application Ser. No. 12/367,679, filed Feb. 9, 2009, now U.S. Pat. No. 8,017,915, which claims the benefit under 35 U.S.C. 119(e) to U.S. Provisional Patent Application Ser. No. 61/036,709, filed Mar. 14, 2008, the contents of each of which are incorporated herein by reference in their entirety.

US Referenced Citations (379)
Number Name Date Kind
3418475 Hudgens Dec 1968 A
3668399 Cahill et al. Jun 1972 A
3794840 Scott Feb 1974 A
3869615 Hoover et al. Mar 1975 A
3906233 Vogel Sep 1975 A
4361902 Brandt et al. Nov 1982 A
4389569 Hattori et al. Jun 1983 A
4503331 Kovacs, Jr. et al. Mar 1985 A
4529882 Lee Jul 1985 A
4563582 Mullani Jan 1986 A
4575868 Ueda et al. Mar 1986 A
4628499 Hammett Dec 1986 A
4642464 Mullani Feb 1987 A
4647779 Wong Mar 1987 A
4677299 Wong Jun 1987 A
4771785 Duer Sep 1988 A
4868844 Nunan Sep 1989 A
5075554 Yunker et al. Dec 1991 A
5099505 Seppi et al. Mar 1992 A
5117445 Seppi et al. May 1992 A
5168532 Seppi et al. Dec 1992 A
5206512 Iwao Apr 1993 A
5207223 Adler May 1993 A
5272344 Williams Dec 1993 A
5317616 Swerdloff et al. May 1994 A
5329567 Ikebe Jul 1994 A
5351280 Swerdloff et al. Sep 1994 A
5390225 Hawman Feb 1995 A
5394452 Swerdloff Feb 1995 A
5396534 Thomas Mar 1995 A
5418827 Deasy et al. May 1995 A
5442675 Swerdloff et al. Aug 1995 A
5548627 Swerdloff Aug 1996 A
5661773 Swerdloff Aug 1997 A
5668371 Deasy et al. Sep 1997 A
5724400 Swerdloff Mar 1998 A
5751781 Brown et al. May 1998 A
5813985 Carroll Sep 1998 A
5818902 Yu Oct 1998 A
5851182 Sahadevan Dec 1998 A
5889834 Vilsmeier et al. Mar 1999 A
5937028 Tybinkowski et al. Aug 1999 A
5946425 Bove, Jr. et al. Aug 1999 A
6023494 Senzig et al. Feb 2000 A
6180943 Lange Jan 2001 B1
6184530 Hines et al. Feb 2001 B1
6188748 Pastyr et al. Feb 2001 B1
6255655 McCroskey et al. Jul 2001 B1
6260005 Yang et al. Jul 2001 B1
6271517 Kroening, Jr. et al. Aug 2001 B1
6281505 Hines et al. Aug 2001 B1
6385288 Kanematsu May 2002 B1
6396902 Tybinkowski et al. May 2002 B2
6438202 Olivera et al. Aug 2002 B1
6449331 Nutt et al. Sep 2002 B1
6449340 Tybinkowski et al. Sep 2002 B1
6455856 Gagnon Sep 2002 B1
6459769 Cosman Oct 2002 B1
6504899 Pugachev et al. Jan 2003 B2
6560311 Shepard et al. May 2003 B1
6618467 Ruchala et al. Sep 2003 B1
6624451 Ashley et al. Sep 2003 B2
6628744 Luhta et al. Sep 2003 B1
6661866 Limkeman et al. Dec 2003 B1
6661870 Kapatoes et al. Dec 2003 B2
6696694 Pastyr et al. Feb 2004 B2
6700949 Susami et al. Mar 2004 B2
6714076 Kalb Mar 2004 B1
6730924 Pastyr et al. May 2004 B1
6735277 McNutt et al. May 2004 B2
6778636 Andrews Aug 2004 B1
6792078 Kato et al. Sep 2004 B2
6794653 Wainer et al. Sep 2004 B2
6810103 Tybinkowski et al. Oct 2004 B1
6810108 Clark et al. Oct 2004 B2
6831961 Tybinkowski et al. Dec 2004 B1
6865254 Nafstadius Mar 2005 B2
6888919 Graf May 2005 B2
6914959 Bailey et al. Jul 2005 B2
6934363 Seufert Aug 2005 B2
6965661 Kojima et al. Nov 2005 B2
6976784 Kojima et al. Dec 2005 B2
6990175 Nakashima et al. Jan 2006 B2
7020233 Tybinkowski et al. Mar 2006 B1
7026622 Kojima et al. Apr 2006 B2
7110808 Adair Sep 2006 B2
7129495 Williams et al. Oct 2006 B2
7154096 Amano Dec 2006 B2
7167542 Juschka et al. Jan 2007 B2
7188999 Mihara et al. Mar 2007 B2
7199382 Rigney et al. Apr 2007 B2
7227925 Mansfield et al. Jun 2007 B1
7242750 Tsujita Jul 2007 B2
7263165 Ghelmansarai Aug 2007 B2
7265356 Pelizzari et al. Sep 2007 B2
7280633 Cheng et al. Oct 2007 B2
7291840 Fritzler et al. Nov 2007 B2
7297958 Kojima et al. Nov 2007 B2
7298821 Ein-Gal Nov 2007 B2
7301144 Williams et al. Nov 2007 B2
7302038 Mackie Nov 2007 B2
7310410 Sohal et al. Dec 2007 B2
7331713 Moyers Feb 2008 B2
7338207 Gregerson et al. Mar 2008 B2
7386099 Kasper et al. Jun 2008 B1
7397901 Johnsen Jul 2008 B1
7397902 Seeber et al. Jul 2008 B2
7405404 Shah Jul 2008 B1
7412029 Myles Aug 2008 B2
7433503 Cherek et al. Oct 2008 B2
7439509 Grazioso et al. Oct 2008 B1
7446328 Rigney et al. Nov 2008 B2
7453983 Schildkraut et al. Nov 2008 B2
7453984 Chen et al. Nov 2008 B2
7469035 Keall et al. Dec 2008 B2
7545911 Rietzel et al. Jun 2009 B2
7555103 Johnsen Jun 2009 B2
7558378 Juschka et al. Jul 2009 B2
7560698 Rietzel Jul 2009 B2
7564951 Hasegawa et al. Jul 2009 B2
7596209 Perkins Sep 2009 B2
7627082 Kojima et al. Dec 2009 B2
7639853 Olivera et al. Dec 2009 B2
7656999 Hui et al. Feb 2010 B2
7657304 Mansfield et al. Feb 2010 B2
7679049 Rietzel Mar 2010 B2
7715606 Jeung et al. May 2010 B2
7742575 Bourne Jun 2010 B2
7755054 Shah et al. Jul 2010 B1
7755055 Schilling Jul 2010 B2
7755057 Kim Jul 2010 B2
7778691 Zhang et al. Aug 2010 B2
7792252 Bohn Sep 2010 B2
7795590 Takahashi et al. Sep 2010 B2
7800070 Weinberg et al. Sep 2010 B2
7820975 Laurence et al. Oct 2010 B2
7839972 Ruchala et al. Nov 2010 B2
7847274 Kornblau et al. Dec 2010 B2
7885371 Thibault Feb 2011 B2
7942843 Tune et al. May 2011 B2
7952079 Neustadter et al. May 2011 B2
7957507 Cadman Jun 2011 B2
7965819 Nagata Jun 2011 B2
7983380 Guertin Jul 2011 B2
8019042 Shukla et al. Sep 2011 B2
8059782 Brown Nov 2011 B2
8063376 Maniawski et al. Nov 2011 B2
8090074 Filiberti et al. Jan 2012 B2
8093568 Mackie Jan 2012 B2
8116427 Kojima et al. Feb 2012 B2
8139713 Janbakhsh Mar 2012 B2
8139714 Sahadevan Mar 2012 B1
8144962 Busch et al. Mar 2012 B2
8148695 Takahashi et al. Apr 2012 B2
8160205 Saracen Apr 2012 B2
8193508 Shchory et al. Jun 2012 B2
8198600 Neustadter et al. Jun 2012 B2
8232535 Olivera et al. Jul 2012 B2
8239002 Neustadter et al. Aug 2012 B2
8269195 Rigney et al. Sep 2012 B2
8278633 Nord et al. Oct 2012 B2
8280002 Bani-Hashemi et al. Oct 2012 B2
8295906 Saunders et al. Oct 2012 B2
8304738 Gagnon et al. Nov 2012 B2
8306185 Bal et al. Nov 2012 B2
8335296 Dehler et al. Dec 2012 B2
8357903 Wang et al. Jan 2013 B2
8384049 Broad Feb 2013 B1
8395127 Frach et al. Mar 2013 B1
8406844 Ruchala et al. Mar 2013 B2
8406851 West et al. Mar 2013 B2
8442287 Fordyce, II et al. May 2013 B2
8461538 Mazin Jun 2013 B2
8461539 Yamaya et al. Jun 2013 B2
8467497 Lu et al. Jun 2013 B2
8483803 Partain et al. Jul 2013 B2
8509383 Lu et al. Aug 2013 B2
8520800 Wilfley et al. Aug 2013 B2
8536547 Maurer, Jr. et al. Sep 2013 B2
8537373 Humphrey Sep 2013 B2
8581196 Yamaya et al. Nov 2013 B2
8588367 Busch et al. Nov 2013 B2
8617422 Koschan et al. Dec 2013 B2
8641592 Yu Feb 2014 B2
8664610 Chuang Mar 2014 B2
8664618 Yao Mar 2014 B2
8712012 O'Connor Apr 2014 B2
8745789 Saracen Jun 2014 B2
8748825 Mazin Jun 2014 B2
8767917 Ruchala et al. Jul 2014 B2
8816307 Kuusela et al. Aug 2014 B2
8873710 Ling et al. Oct 2014 B2
8884240 Shah et al. Nov 2014 B1
8992404 Graf et al. Mar 2015 B2
9061141 Brunker et al. Jun 2015 B2
9179982 Kunz et al. Nov 2015 B2
9205281 Mazin Dec 2015 B2
9360570 Rothfuss et al. Jun 2016 B2
9370672 Parsai et al. Jun 2016 B2
9437339 Echner Sep 2016 B2
9437340 Echner et al. Sep 2016 B2
9498167 Bechtel et al. Nov 2016 B2
9649509 Mazin et al. May 2017 B2
9694208 Mazin et al. Jul 2017 B2
9697980 Ogura et al. Jul 2017 B2
9731148 Olivera et al. Aug 2017 B2
9820700 Mazin Nov 2017 B2
9878180 Schulte et al. Jan 2018 B2
9886534 Wan et al. Feb 2018 B2
9952878 Grimme et al. Apr 2018 B2
9974494 Mostafavi et al. May 2018 B2
10159853 Kuusela et al. Dec 2018 B2
10327716 Mazin Jun 2019 B2
10478133 Levy et al. Nov 2019 B2
10603515 Olcott et al. Mar 2020 B2
10695586 Harper et al. Jun 2020 B2
10745253 Saracen Aug 2020 B2
20020051513 Pugachev et al. May 2002 A1
20020148970 Wong et al. Oct 2002 A1
20020163994 Jones Nov 2002 A1
20020191734 Kojima et al. Dec 2002 A1
20020193685 Mate et al. Dec 2002 A1
20030036700 Weinberg Feb 2003 A1
20030080298 Karplus et al. May 2003 A1
20030105397 Tumer et al. Jun 2003 A1
20030128801 Eisenberg et al. Jul 2003 A1
20030219098 McNutt et al. Nov 2003 A1
20040024300 Graf Feb 2004 A1
20040030246 Townsend et al. Feb 2004 A1
20040037390 Mihara et al. Feb 2004 A1
20040057557 Nafstadius Mar 2004 A1
20040096033 Seppi et al. May 2004 A1
20040120452 Shapiro et al. Jun 2004 A1
20040158416 Slates Aug 2004 A1
20040162457 Maggiore Aug 2004 A1
20040264640 Myles Dec 2004 A1
20050028279 de Mooy Feb 2005 A1
20050089135 Toth et al. Apr 2005 A1
20050104001 Shah May 2005 A1
20050109939 Engler et al. May 2005 A1
20050197564 Dempsey Sep 2005 A1
20050213705 Hoffman Sep 2005 A1
20050228255 Saracen Oct 2005 A1
20050234327 Saracen Oct 2005 A1
20060002511 Miller et al. Jan 2006 A1
20060072699 Mackie Apr 2006 A1
20060113482 Pelizzari et al. Jun 2006 A1
20060124854 Shah Jun 2006 A1
20060173294 Ein-Gal Aug 2006 A1
20060182326 Schildkraut et al. Aug 2006 A1
20060193435 Hara et al. Aug 2006 A1
20060208195 Petrick et al. Sep 2006 A1
20060237652 Kimchy et al. Oct 2006 A1
20070003010 Guertin et al. Jan 2007 A1
20070003123 Fu et al. Jan 2007 A1
20070014391 Mostafavi et al. Jan 2007 A1
20070023669 Hefetz et al. Feb 2007 A1
20070025513 Ghelmansarai Feb 2007 A1
20070043289 Adair Feb 2007 A1
20070053491 Schildkraut et al. Mar 2007 A1
20070055144 Neustadter et al. Mar 2007 A1
20070164239 Terwilliger et al. Jul 2007 A1
20070211857 Urano et al. Sep 2007 A1
20070221869 Song Sep 2007 A1
20070265528 Xu Nov 2007 A1
20070270693 Fiedler et al. Nov 2007 A1
20080002811 Allison Jan 2008 A1
20080031404 Khamene Feb 2008 A1
20080031406 Yan et al. Feb 2008 A1
20080043910 Thomas Feb 2008 A1
20080103391 Dos Santos May 2008 A1
20080128631 Suhami Jun 2008 A1
20080130825 Fu et al. Jun 2008 A1
20080152085 Saracen et al. Jun 2008 A1
20080156993 Weinberg et al. Jul 2008 A1
20080203309 Frach et al. Aug 2008 A1
20080205588 Kim Aug 2008 A1
20080214927 Cherry et al. Sep 2008 A1
20080217541 Kim Sep 2008 A1
20080230705 Rousso et al. Sep 2008 A1
20080253516 Hui et al. Oct 2008 A1
20080262473 Kornblau et al. Oct 2008 A1
20080273659 Guertin Nov 2008 A1
20080298536 Ein-Gal Dec 2008 A1
20090003655 Wollenweber Jan 2009 A1
20090086909 Hui et al. Apr 2009 A1
20090116616 Lu May 2009 A1
20090131734 Neustadter et al. May 2009 A1
20090169082 Mizuta et al. Jul 2009 A1
20090236532 Frach et al. Sep 2009 A1
20090256078 Mazin Oct 2009 A1
20090309046 Balakin Dec 2009 A1
20100010343 Daghighian et al. Jan 2010 A1
20100040197 Maniawski Feb 2010 A1
20100054412 Brinks et al. Mar 2010 A1
20100063384 Kornblau et al. Mar 2010 A1
20100065723 Burbar et al. Mar 2010 A1
20100067660 Maurer, Jr. et al. Mar 2010 A1
20100069742 Partain et al. Mar 2010 A1
20100074400 Sendai Mar 2010 A1
20100074498 Breeding Mar 2010 A1
20100166274 Busch et al. Jul 2010 A1
20100176309 Mackie Jul 2010 A1
20100198063 Huber Aug 2010 A1
20100237259 Wang Sep 2010 A1
20110006212 Shchory et al. Jan 2011 A1
20110044429 Takahashi et al. Feb 2011 A1
20110073763 Subbarao Mar 2011 A1
20110092814 Yamaya et al. Apr 2011 A1
20110105895 Kornblau et al. May 2011 A1
20110105897 Kornblau et al. May 2011 A1
20110118588 Kornblau et al. May 2011 A1
20110198504 Eigen Aug 2011 A1
20110215248 Lewellen et al. Sep 2011 A1
20110215259 Iwata Sep 2011 A1
20110272600 Bert et al. Nov 2011 A1
20110297833 Takayama Dec 2011 A1
20110301449 Maurer, Jr. Dec 2011 A1
20110309252 Moriyasu Dec 2011 A1
20110309255 Bert et al. Dec 2011 A1
20110313231 Guertin et al. Dec 2011 A1
20110313232 Balakin Dec 2011 A1
20120035470 Kuduvalli et al. Feb 2012 A1
20120068076 Daghighian Mar 2012 A1
20120138806 Holmes et al. Jun 2012 A1
20120161014 Yamaya Jun 2012 A1
20120174317 Saracen Jul 2012 A1
20120230464 Ling et al. Sep 2012 A1
20120318989 Park et al. Dec 2012 A1
20120323117 Neustadter et al. Dec 2012 A1
20130025055 Saracen Jan 2013 A1
20130060134 Eshima Mar 2013 A1
20130092842 Zhang et al. Apr 2013 A1
20130111668 Wiggers et al. May 2013 A1
20130193330 Wagadarikar et al. Aug 2013 A1
20130266116 Abenaim et al. Oct 2013 A1
20130327932 Kim et al. Dec 2013 A1
20130343509 Gregerson et al. Dec 2013 A1
20140029715 Hansen et al. Jan 2014 A1
20140107390 Brown et al. Apr 2014 A1
20140163368 Rousso Jun 2014 A1
20140184197 Dolinsky Jul 2014 A1
20140193336 Rousso Jul 2014 A1
20140217294 Rothfuss Aug 2014 A1
20140224963 Guo et al. Aug 2014 A1
20140228613 Mazin et al. Aug 2014 A1
20140239204 Orton et al. Aug 2014 A1
20140257096 Prevrhal Sep 2014 A1
20150018673 Rose et al. Jan 2015 A1
20150076357 Frach Mar 2015 A1
20150078528 Okada Mar 2015 A1
20150168567 Kim et al. Jun 2015 A1
20150177394 Dolinsky et al. Jun 2015 A1
20150190658 Yu Jul 2015 A1
20150276947 Hoenk et al. Oct 2015 A1
20150285922 Mintzer et al. Oct 2015 A1
20160023019 Filiberti et al. Jan 2016 A1
20160073977 Mazin Mar 2016 A1
20160097866 Williams Apr 2016 A1
20160146949 Frach et al. May 2016 A1
20160209515 Da Silva et al. Jul 2016 A1
20160219686 Nakayama et al. Jul 2016 A1
20160266260 Preston Sep 2016 A1
20160273958 Hoenk et al. Sep 2016 A1
20160299240 Cho et al. Oct 2016 A1
20160361566 Larkin et al. Dec 2016 A1
20160374632 David Dec 2016 A1
20170014648 Mostafavi Jan 2017 A1
20170052266 Kim et al. Feb 2017 A1
20170220709 Wan et al. Aug 2017 A1
20170242136 O'Neill et al. Aug 2017 A1
20170281975 Filiberti et al. Oct 2017 A1
20180133518 Harper et al. May 2018 A1
20180292550 Xu et al. Oct 2018 A1
20190018154 Olcott et al. Jan 2019 A1
20190070437 Olcott et al. Mar 2019 A1
20190143145 Laurence, Jr. et al. May 2019 A1
20200215355 Olcott et al. Jul 2020 A1
20200222724 Mazin et al. Jul 2020 A1
Foreign Referenced Citations (56)
Number Date Country
1681436 Oct 2005 CN
1960780 May 2007 CN
101970043 Feb 2011 CN
10-2008-053321 May 2010 DE
1 501 604 Dec 2009 EP
1 698 234 Apr 2010 EP
2 188 815 Nov 2011 EP
2 687 259 Jan 2014 EP
2 874 702 Sep 2016 EP
1 664 752 Jun 2017 EP
208396 Dec 2010 IL
09-33658 Feb 1997 JP
9-189769 Jul 1997 JP
H-11-290466 Oct 1999 JP
2000-105279 Apr 2000 JP
2001-340474 Dec 2001 JP
2003-534823 Nov 2003 JP
2004-513735 May 2004 JP
2006-145281 Jun 2006 JP
2007-502166 Feb 2007 JP
2007-507246 Mar 2007 JP
2008-173299 Jul 2008 JP
2010-517655 May 2010 JP
9520013 Feb 1997 NL
WO-8910090 Nov 1989 WO
WO-9522241 Aug 1995 WO
WO-0015299 Mar 2000 WO
WO-03076003 Sep 2003 WO
WO-03076003 Sep 2003 WO
WO-2004017832 Mar 2004 WO
WO-2004017832 Mar 2004 WO
WO-2004105574 Dec 2004 WO
WO-2004105574 Dec 2004 WO
WO-2005018734 Mar 2005 WO
WO-2005018734 Mar 2005 WO
WO-2005018735 Mar 2005 WO
WO-2005018735 Mar 2005 WO
WO-2005110495 Nov 2005 WO
WO-2007045076 Apr 2007 WO
WO-2007094002 Aug 2007 WO
WO-2007094002 Aug 2007 WO
WO-2007124760 Nov 2007 WO
WO-2008011725 Jan 2008 WO
WO-2008019118 Feb 2008 WO
WO-2008019118 Feb 2008 WO
WO-2008024463 Feb 2008 WO
WO-2008024463 Feb 2008 WO
WO-2009111580 Sep 2009 WO
WO-2009111580 Sep 2009 WO
WO-2009114117 Sep 2009 WO
WO-2009114117 Sep 2009 WO
WO-2010015358 Feb 2010 WO
WO-2010110255 Sep 2010 WO
WO-2012135771 Oct 2012 WO
WO-2015042510 Mar 2015 WO
WO-2016097977 Jun 2016 WO
Non-Patent Literature Citations (66)
Entry
Chang, J.Y. et al. (2008). “Image-guided radiation therapy for non-small cell lung cancer,” J. Thorac. Oncol. 3(2):177-186.
Chen, Y. et al. (2011). Dynamic tomotherapy delivery, Am. Assoc. Phys. Med. 38:3013-3024.
Dieterich, S. et al, (2003), “Skin respiratory motion tracking for stereotactic radiosurgery using the CyberKnife,” Elsevier Int'l Congress Series 1256:130-136.
Erdi, Y.E. (2007). “The use of PET for radiotherapy,” Curr. Medical Imaging Reviews 3(1):3-16.
Extended European Search Report dated Mar. 31, 2017, for European Application No, 09 719 473.2, filed on Mar. 9, 2009, 8 pages.
Fan, Q. et al. (2012). “Emission Guided Radiation Therapy for Lung and Prostrate Cancers: A Feasibility Study on a Digital Patient,” Med. Phys. 39(11):7140-7152.
Fan, Q. et al. (2013). “Toward a Planning Scheme for Emission Guided Radiation Therapy (EGRT): FDG Based Tumor Tracking in a Metastatic Breast Cancer Patient,” Med. Phys. 40(8): 12 pages.
Final Office Action dated Aug. 15, 2012, for U.S. Appl. No. 13/209,275, filed Aug. 12, 2011, 8 pages.
Galvin, J.M. (2018). “The muitileaf collimator—A complete guide,” 17 total pages.
Gibbons, J.P. (2004). “Dose calculation and verification for tomotherapy,” 2004 ACMP Meeting, Scottsdale, AZ., 71 total pages.
Glendinning, A.G. et al. (2001). “Measurement of the response of Gd2O2S:Tb phosphor to 6 MV x-rays,” Phys. Mol. Biol. 46:517-530.
Handsfield, L.L. et al. (2014). “Phantomless patient-specific TornoTherapy QA via delivery performance monitoring and a secondary Monte Carlo dose calculation,” Med. Phys. 41:101703-1-101703-9.
International Search Report dated May 4, 2009, for PCT Application No. PCT/US2009/01500, filed on Mar. 9, 2009, 3 pages.
International Search Report dated Mar. 7, 2018, for PCT Application No. PCT/US2017/061848, filed on Nov. 15, 2017, 4 pages.
International Search Report dated Oct. 2, 2018, for PCT Application No. PCT/US2018/041700, filed Jul. 11, 2018, 2 pages.
International Search Report dated Oct. 24, 2018, for PCT Application No. PCT/US2018/046132, filed Aug. 9, 2018, 2 pages.
International Search Report dated Jan. 30, 2019, for PCT Application No. PCT/US2018/061099, filed on Nov. 14, 2018, 4 pages.
Kapatoes, J.M. et al. (2001). “A feasible method for clinical delivery verification and dose reconstruction in tomotherapy,” Med. Phys. 28:528-542.
Keall, P.J. et al. (2001). “Motion adaptive x-ray therapy: a feasibility study,” Phys. Med. Biol. 46:1-10.
Kim, H. et al. (2009). “A multi-threshold method for the TOF-PET Signal Processing,” Nucl. Instrum. Meth. Phys. Res. A. 602:618-621.
Krouglicof, N. et al. (2013). “Development of a Novel PCB-Based Voice Coil Actuator for Opto-Mechatronic Applications,” presented at IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Tokyo, Japan, Nov. 3-7, 2013, pp. 5634-5640.
Langen, K.M. et al, (2010). “QA for helical tomotherapy: report of the AAPM Task Group 148,” Med. Phys. 37:4817-4853.
Macke, T,R. et al, (Nov.-Dec. 1993). “Tomotherapy: A New Concept for the Delivery of Dynamic Conformal Radiotherapy,” Med. Phys. 20(6):1709-1719.
Mazin, S. R. et al. (2010). “Emission-Guided Radiation Therapy: Biologic Targeting arid Adaptive Treatment,” Journal of American College of Radiology 7(12):989-990.
Non-Final Office Action dated Jan. 10, 2011, for U.S. Appl. No. 12/367,679, filed Feb. 9, 2009, 9 pages.
Non-Final Office Action dated Feb. 28, 2012, for U.S. Appl. No. 13/209,275, filed Aug. 12, 2011, 8 pages.
Non-Final Office Action dated Sep. 19, 2013, for U.S. Appl. No. 13/895,255, filed May 15, 2013, 8 pages.
Notice of Allowance dated Jul. 25, 2011, for U.S. Appl. No. 12/367,679, filed Feb. 9, 2009, 7 pages.
Notice of Allowance dated Apr. 9, 2014, for U.S. Appl. No. 13/895,255, filed May 15, 2013, 7 pages.
Notice of Allowance dated Oct. 27, 2015, for U.S. Appl. No. 14/278,973, filed May 15, 2014, 8 pages.
Notice of Allowance dated Mar. 27, 2013, for U.S. Appl. No. 13/209,275, filed Aug. 12, 2011, 9 pages.
Notice of Allowance dated Oct. 5, 2017, for U.S. Appl. No. 14/951,194, filed Nov. 24, 2015, 11 pages.
Notice of Allowance dated Apr. 4, 2019, for U.S. Appl. No. 15/807,383, filed Nov. 8, 2017, 11 pages.
North Shore LIJ (2008). IMRT treatment plans: Dosimetry measurements & monitor units validation, 133 total pages.
Papanikolaou, N. et al. (2010). “MU-Tomo: Independent dose validation software for helical tomo therapy,” J. Cancer Sci. Ther. 2:145-152.
Parodi, K. (2015). “Vision 20/20: Positron emission tomography in radiation therapy planning, delivery, arid monitoring,” Med. Phys. 42:7153-7168.
Prabhakar, R. et al. (2007). “An Insight into PET-CT Based Radiotherapy Treatment Planning,” Cancer Therapy (5):519-524.
Schleifring (2013). Slip Ring Solutions—Technology, 8 total pages.
Tashima, H. et al. (2012). “A Single-Ring Open PET Enabling PET Imaging During Radiotherapy,” Phys. Med. Biol. 57(14):4705-4718.
TornoTherapy® (2011). TOMOHD Treatment System, Product Specifications, 12 total pages.
Varian Medical Systems (2004). “Dynamic Targeting™ Image-Guided Radiation Therapy—A Revolution in Cancer Care,” Business Briefing: US Oncology Review, Abstract only, 2 pages.
Wikipedia (2016), “Scotch yoke,” Retrieved from https://en.wikipedia.org/wiki/Scotch_yoke, 3 pages.
Willoughby, T. et al. (2012). “Quality assurance for nonradiographic radiotherapy localization and positioning systems: Report of task group 147” Med. Phys. 39:1728-1747.
Written Opinion of the International Searching Authority dated May 4, 2009, for PCT Application No. PCT/US2009/01500, filed on Mar. 9, 2009, 5 pages.
Written Opinion of the International Searching Authority dated Mar. 7, 2018, for PCT Application No. PCT/US2017/061848, filed Nov. 15, 2017, 5 pages.
Written Opinion of the International Searching Authority dated Oct. 2, 2018, for PCT Application No. PCT/US2018/041700, filed on Jul. 11, 2018, 19 pages.
Written Opinion of the International Searching Authority dated Oct. 24, 2018, for PCT Application No. PCT/US2018/046132, filed on Aug. 9, 2018, 7 pages.
Written Opinion of the International Searching Authority dated Jan. 30, 2019, for PCT Application No. PCT/US2018/061099, filed on Nov. 14, 2018, 11 pages.
Yamaya, T. et al. (2008). “A proposal of an open PET geometry,” Physics in Med. and Biology 53:757-773.
Corrected Notice of Allowability dated Jan. 29. 2020, for U.S. Appl. No. 16/100,054, filed Aug. 9, 2018, 4 pages.
Extended European Search Report dated Oct. 30, 2020, for EP Application No. 20 179 036.7, filed on Mar. 9, 2009, 12 pages.
Lu, W. (2009). “Real-time motion-adaptive-optimization (MAO) in tornotherapy,” Phys. Med. Biol. 54:4373-4398.
Lu, W. (2008). “Real-time motion-adaptive delivery (MAD) using binary MLC: I. Static beam (topotherapy) delivery,” Phys. Med. Biol. 53:6491-6511.
McMahon, R. et al. (2008). “A real-time dynamic-MLC control algorithm for delivering IMRT to targets undergoing 2D rigid motion in the beam's eye view,” Med. Phys. 35:3875-3888.
Non-Final Office Action dated Sep. 19, 2019, for U.S. Appl. No. 16/217,417, filed Dec. 12, 2018, 7 pages.
Non-Final Office Action dated Oct. 29, 2020, for U.S. Appl. No. 16/834.956, filed Mar. 30. 2020, 7 pages.
Non-Final Office Action dated Jan. 7, 2020, for U.S. Appl. No. 15/814,222, filed Nov. 15, 2017, 13 pages.
Non-Final Office Action dated Oct. 5, 2020, for U.S. Appl. No. 16/887,896, filed May 29, 2020, 62 pages.
Non-Final Office Action dated Nov. 3, 2020, for U.S. Appl. No. 16/818,325, filed Mar. 13, 2020, 9 pages.
Notice of Allowance dated Dec. 4, 2019, for U.S. Appl. No. 16/100,054, filed Aug. 9, 2018, 13 pages.
Notice of Allowance dated Jan. 21, 2020, for U.S. Appl. No. 16/193,725, filed Nov. 16, 2018, 7 pages.
Notice of Allowance dated Mar. 13, 2020, for U.S. Appl. No. 16/217,417, filed Dec. 12, 2018, 6 pages.
Notice of Allowance dated Apr. 10, 2020, for U.S. Appl. No. 16/033,125, filed Jul. 11, 2018, 18 pages.
Notice of Allowance dated Apr. 30, 2020, for U.S. Appl. No. 15/814,222, filed Nov. 15, 2017, 10 pages.
Olivera, G.H. et al. (2000). “Modifying a plan delivery without re-optimization to account for patient offset in tomotherapy,” Proceedings of the 22nd Annual EMBS International Conference, Jul. 23-28, 2000, Chicago, IL, pp. 441-444.
ViewRay's MRIDIAN LINAC enables radiosurgery with MRI vision for cancer therapy, (2017). YouTube video located at https://wwwyoutube.com/watch?v=zm3g-BISYDQ, PDF of Video Screenshot Provided.
Related Publications (1)
Number Date Country
20190357859 A1 Nov 2019 US
Provisional Applications (1)
Number Date Country
61036709 Mar 2008 US
Continuations (6)
Number Date Country
Parent 15807383 Nov 2017 US
Child 16425416 US
Parent 14951194 Nov 2015 US
Child 15807383 US
Parent 14278973 May 2014 US
Child 14951194 US
Parent 13895255 May 2013 US
Child 14278973 US
Parent 13209275 Aug 2011 US
Child 13895255 US
Parent 12367679 Feb 2009 US
Child 13209275 US